These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37074571)

  • 1. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
    Lu X; Yan S; Koral KA; Chen Z
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
    [No Abstract]   [Full Text] [Related]  

  • 3. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
    Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
    Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
    Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
    Cao Y; Lu M; Sun Y; Gong J; Li J; Lu Z; Li J; Zhang X; Li Y; Peng Z; Zhou J; Wang X; Shen L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):779-789. PubMed ID: 35166929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
    Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
    Xu J
    Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
    Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
    Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
    Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
    Das S; Phillips S; Lee CL; Agarwal R; Bergsland E; Strosberg J; Chan JA; LaFerriere H; Ramirez RA; Berlin J; Dasari A
    Eur J Cancer; 2023 Mar; 182():43-52. PubMed ID: 36738541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
    Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
    ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
    Wang-Gillam A; Schelman W; Ukrainskyj S; Chien C; Gonzalez M; Yang Z; Kania M; Yeckes-Rodin H
    Invest New Drugs; 2023 Dec; 41(6):851-860. PubMed ID: 37796398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
    Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
    J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）].
    Chinese Multidisciplinary Expert Consensus on the Rational Use of Surufatinib in Clinical Practice-Editorial Board Group
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):930-939. PubMed ID: 39414593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
    Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L
    Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surufatinib: First Approval.
    Syed YY
    Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.